October 25, 2019 - 9:00am

Health and Human Services Commission, Brown Heatly Building, Public Hearing Room, Room 1400
4900 North Lamar Blvd.
Austin, TX 78751

Add to My Calendar

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings the day and time of the meeting.

  1. Call to order
  2. Approval of minutes from July 25, 2019 (vote required)
  3. New business:
    Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Androgenic agents, topical
    2. Antibiotics, gastrointestinal (GI)
    3. Antibiotics, topical
    4. Antibiotics, vaginal
    5. Anticonvulsants (class will not be reviewed but Board will hear public testimony)
    6. Antiemetics/antivertigo agents
    7. Antifungals, oral
    8. Antifungals, topical
    9. Antihistamines - first generation
    10. Antiparasitics, topical
    11. Antipsychotics
    12. Antivirals, topical
    13. Bone resorption suppression and related agents
    14. Colony stimulating factors
    15. Cytokine and Cell Adhesion Molecule (CAM) antagonists
    16. Epinephrine, self-injected
    17. GI motility, chronic
    18. Growth hormone
    19. Hepatitis C agents
    20. Hypoglycemics, incretin mimetics/enhancers
    21. Hypoglycemics, insulin and related agents
    22. Hypoglycemics, meglitinides
    23. Hypoglycemics, metformin
    24. Hypoglycemics, sodium-glucose cotransporter-2 inhibitors (SGLT2)
    25. Hypoglycemics, thiazolidinedione (TZD)
    26. Macrolides/Ketolides
    27. aa. Opiate dependence treatments
    28. bb. Penicillins
    29. cc. Tetracyclines
  4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
    1. Emgality Syringe 100 mg / Antimigraine Agents, Other 
    2. Tadalafil / Benign Prostatic Hyperplasia (BPH) Treatments 
    3. Katerzia / Calcium Channel Blockers
    4. Cutaquig / Immune Globulins
    5. Ezallor Sprinkle / Lipotropics, Statins
    6. Lidopure, Zilacaine Patch / Neuropathic Pain
    7. Beser Kit / Steroids, Topical Medium
    8. Adhansia XR, Evekeo ODT, Jornay PM, Sunosi / Stimulants and Related Agents
  5. Therapeutic and Clinical Drug Reviews and Updates:   Matt Lennertz, Pharm. D., Magellan Medicaid Administration
  6. Executive work session
    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  7. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
  8. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Atypical antipsychotics – long-acting injectables
    2. Atypical antipsychotics – oral
    3. Insulins
    4. Nitazoxanide
    5. Promethazine use in children 2 years of age or younger
    6. Quetiapine, low-dose
  9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Respiratory Disease Management
    2. Report on recent retrospective DUR intervention outcomes:
      1. Diabetes Disease Management 2018
      2. Rheumatoid Arthritis Management 2018
      3. Opioid Prescribing
    3. Retrospective DUR proposals (vote required)
      1. Opioid/Benzodiazepine/Antipsychotics (Support Act)
      2. Pain Management with Opioids
  10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Bonjesta/Diclegis (doxylamine/pyridoxine) – new criteria
    2. Cytokine and CAM Antagonists – addition of Rinvoq (upadacitinib)
    3. Diacomit (stiripentol) – new criteria
    4. Sunosi (solriamfetol) – addition of Sunosi to current Provigil/Nuvigil criteria
  11. Next meeting date: January 24, 2020
  12. Adjourn

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Alish Valdez, DUR/Formulary Support Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6136 or VDP-Advisory@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Valdez at 512-707-6136 at least 72 hours before the meeting so appropriate arrangements can be made.